Overview of Dr. Dickson
Dr. Mark Dickson is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 14 years. He is one of 464 doctors at Memorial Sloan Kettering Cancer Center and one of 88 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 80 publications and over 500 citings.
Office
Memorial Sloan Kettering Cancer Center New York
1275 York Avenue
New York, NY 10021- Is this information wrong?
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2010
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2003 - 2006
Columbia University Vagelos College of Physicians and SurgeonsClass of 2003
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2020 - 2025
NY State Medical License 2010 - 2025
CT State Medical License 2023 - 2024
NC State Medical License 2020 - 2022- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials Start of enrollment: 2008 May 14
- Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma Start of enrollment: 2010 Aug 01
- PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Start of enrollment: 2010 Sep 23
Publications & Presentations
PubMed
- GLI1 Co-Amplification in Well-differentiated/Dedifferentiated Liposarcomas: Clinicopathologic and Molecular Analysis of 92 Cases.Aarti E Sharma, Mark Dickson, Samuel Singer, Meera R Hameed, Narasimhan P Agaram> ;Modern Pathology. 2024 Apr 13
- Phase II Trial ofSirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update.Ganjoo, K., Van Tine, B., Chugh, R., Hornick, J., Du, H., Ding, L., Schmid, A., Navarro, W., Kwiatkowski, D., Wagner, A., Ravi, V., Riedel, R., Cranmer, L., Gordon, E....> ;Journal of Clinical Oncology. 2024 Mar 1
- Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma.Gleason, C., Dickson, M., Klein Dooley, M., Antonescu, C., Gularte-Mérida, R., Benitez, M., Delgado, J., Kataru, R., Tan, M., Bradic, M., Adamson, T., Seier, K., Richa...> ;Clinical Cancer Research. 2024 Feb 16
- Join now to see all
Journal Articles
- TP53 Mutations Emerge with HDM2 Inhibitor SAR405838 Treatment in De-Differentiated LiposarcomaMark A Dickson, Edwin Choy, Nature
Press Mentions
Aadi Bioscience Breakthrough Therapy Nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComaNovember 14th, 2019
Big, Fat Tumors: Liposarcomas Can Top 70 PoundsOctober 5th, 2018
Hospital Affiliations
Memorial Sloan Kettering Cancer CenterNew York, New York- Memorial Hospital for Cancer and allied DiseasesBasking Ridge, New Jersey
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
